Danhong Yang

Dr. Danhong Yang


Research Focus & Metrics

Academic Career Length

16Years (2011-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2011 in World Journal of Gastroenterology
Verified
Journal Article
Open access
DYDanhong Yang
Danhong Yang
To study the effect of salvianolate on expression of tumor necrosis factor (TNF)-α and interleukin (IL)-6 mRNA in small intestine of cirrhotic rats. Cirrhosis in rats was induced using CCl4 (0.3 mL/kg). Rats were randomly divided into non-treatment group, low-dose salvianolate (12 mg/kg) treatment group, medium-dose salvianolate (24 mg/kg) treatment group, and high-dose salvianolate (48 mg/kg) treatment group, and treated for 2 wk. Another 10 healthy rats served as a normal control group. Mortality of cirrhotic rats in each group was evaluated after treatment with salvianolate. Serum samples were taken from portal vein for the detection of endotoxin. Morphological changes in tissue samples from the ileocecum were observed under a light microscope. Expression of TNF-α and IL-6 mRNA in the small intestine of rats was analyzed by real-time reverse-transcriptase polymerase chain reaction. The mortality of cirrhotic rats in the non-treatment group was 37.5%. No cirrhotic rat died in the high-dose salvianolate treatment group. The serum endotoxin level was significantly higher in the non-treatment group than in the salvianolate treatment and normal control groups. The intestinal mucosal and villous atrophy, necrosis and shedding of the intestinal mucosal epithelium, observed in the non-treatment group, were reversed in different salvianolate treatment groups. The TNF-α and IL-6 mRNA expression levels in small intestine were significantly lower in different salvianolate treatment groups than in the non-treatment group. Salvianolate can reduce the endotoxin level, ameliorate the injury of intestinal mucosa, and inhibit the expression of TNF-α and IL-6 mRNA in small intestine of cirrhotic rats.

1 January 2012 in World Journal of Gastroenterology
Verified
Journal Article
Open access
DYDanhong Yang
Danhong Yang
To study the effect of salvianolate on tight junctions (TJs) and zonula occludens protein 1 (ZO-1) in small intestinal mucosa of cirrhotic rats. Cirrhosis was induced using carbon tetrachloride. Rats were randomly divided into the untreated group, low-dose salvianolate (12 mg/kg) treatment group, medium-dose salvianolate (24 mg/kg) treatment group, and high-dose salvianolate (48 mg/kg) treatment group, and were treated for 2 wk. Another 10 healthy rats served as the normal control group. Histological changes in liver tissue samples were observed under a light microscope. We evaluated morphologic indices of ileal mucosa including intestinal villi width and thickness of mucosa and intestinal wall using a pathological image analysis system. Ultrastructural changes in small intestinal mucosa were investigated in the five groups using transmission electron microscopy. The changes in ZO-1 expression, a tight junction protein, were analyzed by immunocytochemistry. The staining index was calculated as the product of the staining intensity score and the proportion of positive cells. In the untreated group, hepatocytes showed a disordered arrangement, fatty degeneration was extensive, swelling was obvious, and disorganized lobules were divided by collagen fibers in hepatic tissue, which were partly improved in the salvianolate treated groups. In the untreated group, abundant lymphocytes infiltrated the fibrous tissue with proliferation of bile ducts, and collagen fibers gradually decreased and damaged hepatic lobules were partly repaired following salvianolate treatment. Compared with the untreated group, no differences in intestinal villi width between the five groups were observed. The villi height as well as mucosa and intestinal wall thickness gradually thickened with salvianolate treatment and were significantly shorter in the untreated group compared with those in the salvianolate treatment groups and normal group (P < 0.01). The number of microvilli decreased and showed irregular lengths and arrangements in the untreated group. The intercellular space between epithelial cells was wider. The TJs were discontinuous, which indicated disruption in TJ morphology in the untreated group. In the treated groups, the microvilli in the intestinal epithelium were regular and the TJs were gradually integrated and distinct. The expression of ZO-1 decreased in the small intestine of the untreated cirrhotic rats. The high expression rate of ZO-1 in ileal mucosa in the untreated group was significantly lower than that in the medium-dose salvianolate group (21.43% vs 64.29%, χ(2) = 5.25, P < 0.05), high-dose salvianolate group (21.43% vs 76.92%, χ(2) = 8.315, P < 0.01) and normal group (21.43% vs 90%, χ(2) = 10.98, P < 0.01). Salvianolate improves liver histopathological changes, repairs intestinal mucosa and TJ structure, and enhances ZO-1 expression in the small intestinal mucosa in cirrhotic rats.

19 August 2025 in BMC Infectious Diseases
Verified
Journal Article
Open access
PDF file
MWMiaomiao Wu
Miaomiao Wu
DYDanhong Yang
Danhong Yang
XLXi Li
Xi Li
YHYicheng Huang
Yicheng Huang
HPHongying Pan
Hongying Pan
The mortality rate of secondary bloodstream infection (BSI) derived from the intestinal colonization of carbapenem-resistant Klebsiella pneumoniae (CRKP) is extremely high. This investigation aimed at clarifying the risk factors and prognosis of BSIs resulting from the initial colonisation of CRKP. In this retrospective, cross-sectional study, we analyzed the clinical data of 167 patients with CRKP colonization who received active screening during hospitalization at Zhejiang Provincial People’s Hospital from January 2019 to December 2021. The cohort consisted of 34 patients with BSI (CRKP BSI group) and 133 patients without BSI (No-BSI CRKP group).Logistic regression was employed to identify risk factors for progression from CRKP intestinal colonization to secondary BSI.Cox proportional hazards regression models were used to analyze independent risk factors for 28-day crude mortality from CRKP BSI. Multivariable analysis revealed that previous use of carbapenems (odds ratio [OR]:4.14, 95% confidence interval [CI]: 1.07–16.0, P = 0.040), corticosteroid use (OR: 3.18, 95% CI: 1.16–8.74, P = 0.025), and agranulocytosis (OR: 7.54, 95% CI: 2.09–27.2; P = 0.002) were independent risk factors for BSI in patients with CRKP rectal colonization. The overall mortality rate for CRKP infection was 20.4% (34/167), and the crude 28-day mortality rate for CRKP BSI was 44.1% (15/34), which was independently associated with hematologic neoplasms (P < 0.001). Among the 11 genotypically evaluated CRKP strains, 10 harbored the blaKPC−2 gene. Neutrophil deficiency, previous use of carbapenems, and corticosteroid use are risk factors for BSI following CRKP colonization. Patients with hematologic neoplasms associated with CRKP infection are at high risk of death. Patients with clinical risk factors should be identified early, and targeted intervention measures should be taken to optimize antibiotic use and reduce the risk of subsequent BSI.

7 May 2021 in World Journal of Gastroenterology
Verified
Journal Article
Open access
DYDanhong Yang
Danhong Yang
WWWei-Ping Wang
Wei-Ping Wang
QZQiang Zhang
Qiang Zhang
HPHong-Ying Pan
Hong-Ying Pan
YHYi-Cheng Huang
Yi-Cheng Huang
JZJia-Jie Zhang
Jia-Jie Zhang
Hepatocellular carcinoma progression in hepatitis B virus-related cirrhosis patients receiving nucleoside (acid) analogs therapy: A retrospective cross-sectional study

29 August 2024 in BMJ Open
Verified
Journal Article
Open access
PDF file
WYWenqianzi Yang
Wenqianzi Yang
XZXuemei Zhen
Xuemei Zhen
XSXueshan Sun
Xueshan Sun
XZXuepei Zhang
Xuepei Zhang
DYDanhong Yang
Danhong Yang
DHDong Hengjin
Dong Hengjin
Objectives: This analysis aims to better reflect the value of new antibiotic treatment strategies, thereby informing clinical antibiotic use, antimicrobial reimbursement and/or hospital formulary decision-making in China. Design: We adapted a published and validated dynamic disease transmission and cost-effectiveness model to evaluate the clinical and economic outcomes of introducing a new antibiotic, ceftazidime/avibactam (CAZ-AVI) for treating resistant infections in Zhejiang province, China. Outcomes were assessed over a 10-year infectious period and an annual discount rate of 5%. Costs were extracted from the hospital’s Health Information System (HIS) and obtained after data cleaning, aggregation and discounting. Setting: The Chinese healthcare system perspective. Participants: 10 905 patients in a Chinese tier-3 hospital from 2018 to 2021 with any of the three common infections (complicated intra-abdominal infection (cIAI), hospital-acquired/ventilator-associated pneumonia (HAP/VAP) and infections with limited treatment options (LTO)) caused by three common resistant pathogens ( Escherichia coli, Klebsiella spp. and Pseudomonas aeruginosa ). Interventions: (1) Current treatment strategy (piperacillin-tazobactam (pip/taz) and meropenem); (2) CAZ-AVI at the third line; (3) CAZ-AVI at the second line; (4) CAZ-AVI at the first line; (5) CAZ/AVI first line, two lines diversified (i.e., equal pip/taz and CAZ-AVI at the first line; meropenem at the last line) and (6) CAZ/AVI first line, all-lines diversified. Primary outcome measures: Quality-adjusted life years (QALYs) lost, hospitalisation costs and incremental net monetary benefit (INMB) were used to assess cost-effectiveness. Results: Over 10 years, the introduction of CAZ-AVI to the current treatment strategy led to lower hospitalisation costs and more QALYs across all five treatment strategies, with between 68 284 and 78 571 QALYs gained whilst saving up to US$236.37 for each additional QALY gained. The INMB of introducing CAZ-AVI is estimated up to US$3 550 811 878. Conclusions: Introducing CAZ-AVI had a positive impact on clinical and economic outcomes for treating antimicrobial resistance, and diversifying the antibiotics use early in the treatment might yield the best benefits.